Health Care · Laboratory Analytical Instruments

LAB STANDARD BIOTOOLS INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1162194124 filings
Russell 2000

LAB at a glance

STANDARD BIOTOOLS INC. (LAB, SEC CIK 1162194) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), STANDARD BIOTOOLS INC. (LAB) reported revenue of $85.3 million (down 51.1% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$0.20.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding STANDARD BIOTOOLS INC. (LAB) shares worth $72.7 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Carey Thomas D. on November 5, 2026 of 75,000 shares at $0.63 per share.
  • In the last 90 days, LAB insiders reported 1 open-market purchase ($47K) and 0 open-market sales ($0) on Form 4, a net purchase of $47K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$85.3M
−51.1% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$47K
13F holders
27 funds
$72.7M · −1 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 5.02 · Item 7.01 · Item 5.07

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Merger agreement risk: representations and warranties expire at Closing, eliminating post-closing indemnification for undisclosed liabilities
  • Legal risk: July and August 2026 stockholder demands could delay or enjoin the Merger
  • CVR monetization risk: no payments if legacy-business proceeds, investment proceeds, contingent payments, and Parent Net Cash surplus are absent
  • Dilution risk: CVR settlements may issue up to 76,000,000 combined-company shares
  • Liquidity risk: unsecured CVRs are subordinated to senior obligations and lack an established trading market

Management Discussion & Analysis

  • Revenue $19.385M, down $0.167M or 1% YoY, with instruments up 18% to $5.998M
  • Gross margin 55.9% vs 48.5% YoY, gross profit $10.828M vs $9.484M
  • Services and other revenue weakest line, down 12% to $5.057M; consumables down 4% to $8.330M
  • Cash, cash equivalents and investments $559.4M vs $213.3M at December 31, 2025; operating cash use $63.1M
  • Merger expected in fourth quarter of 2026; liquidity expected sufficient for at least the next 12 months

AI summary of the LAB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stockholders approved the Post-Closing Equity Incentive Plan and Post-Closing ESPP
  • Both plans activate only if the merger closes, linking employee incentives to transaction completion

Item 7.01: Regulation FD Disclosure

  • Stockholders approved all proposals at the November 19, 2026 Special Meeting
  • Approval clears the company’s submitted corporate actions, with specific effects detailed in Exhibit 99.1

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Special meeting quorum: 281.7M votes, representing 71.38% of voting power
  • Merger share issuance approved: 274.1M for, 7.6M against, enabling Nasdaq-compliant equity consideration

Item EX-99.1: Item EX-99.1

  • Stockholders approved all proposals for the Treeline Biosciences merger and Mass Cytometry business sale
  • Treeline merger targeted for fourth quarter 2026, subject to customary closing conditions
Filed Nov 16, 2026Full analysis →

Item 8.01: Other Events

  • Merger vote remains scheduled for November 19, 2026, with SEC-effective proxy materials supplemented before stockholder approval
  • 15 demand letters and two shareholder lawsuits allege material omissions, creating litigation, delay and transaction-cost risks
Filed Nov 3, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Microfluidics business sale to ARCHIMED closed on November 3, 2026
  • Transaction completes Standard BioTools’ previously announced divestiture and transfers future business ownership to ARCHIMED

Item EX-99.1: Item EX-99.1

  • ARCHIMED completed the acquisition of Standard BioTools’ Microfluidics Business, separating it from LAB’s operating portfolio
  • Business relaunched as Biomark Scientific, retaining the Biomark platform, Biomark X9 system and existing team

AI summaries of LAB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LAB

Don't miss the next LAB filing

  • Alerts as it files. A push when LAB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LAB, by share count.
  • Ask anything. An AI agent that reads every LAB filing and answers with sources.

LAB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Carey Thomas D.BuyNov 5, 2026$0.63
Kim Hanjoon AlexFAug 20, 2026$0.67
Mackay SeanFAug 20, 2026$0.67
Egholm MichaelFAug 20, 2026$0.67
Egholm MichaelFAug 3, 2026$0.87
Kim Hanjoon AlexFJul 23, 2026$0.90
Mackay SeanAJun 20, 2026-
Cox TroyAJun 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$174.4M$85.3M
Gross Profit-$84.3M$42.5M
Operating Income--$175.2M-$110.2M
Net Income--$138.9M-$74.9M
Gross Margin-48.3%49.9%
Op. Margin--100.5%-129.2%
Net Margin--79.6%-87.8%
Balance Sheet
Total Assets$323.1M$612.3M$567.8M
Equity-$471.7M$424.3M
ROE--29.4%-17.7%
Per Share
EPS-$-0.52$-0.20
Cash Flow
Operating CF--$143.5M-$74.3M
CapEx$2.8M$8.4M$8.3M

Source: XBRL data in STANDARD BIOTOOLS INC. (LAB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LAB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LAB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$72.7M
Q2 202628$81.1M
Q1 202628$108.7M
Q4 202526$165.5M
Q3 202525$162.7M
Q2 202526$150.8M
Q1 202522$116.1M
Q4 202419$171.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LAB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
8-KNov 16, 2026Analysis-
4Nov 5, 2026--
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
8-KOct 5, 2026Analysis-
8-KSep 30, 2026Analysis-
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
SC 13GAug 14, 2026-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Aug 4, 2026--
8-KJul 29, 2026Analysis-
8-KJul 28, 2026Analysis-
4Jul 27, 2026--
8-KJul 24, 2026Analysis-
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--

Related Health Care companies

All Health Care →

LAB SEC filings: frequently asked questions

Are LAB insiders buying or selling?

In the last 90 days, STANDARD BIOTOOLS INC. (LAB) officers, directors and 10% owners reported 1 open-market purchase worth $46,898 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LAB stock?

As of September 30, 2026, the largest STANDARD BIOTOOLS INC. (LAB) holders among the 13F filers tracked by SignalX were Viking Global Investors ($43.4 million), Vanguard Capital Management LLC ($9.3 million), BlackRock ($6.1 million), D.E. Shaw & Co ($3.0 million), Morgan Stanley ($2.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LAB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), STANDARD BIOTOOLS INC. (LAB) reported revenue of $85.3 million (down 51.1% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$0.20. The figures come from the XBRL data in the 10-K.

What did LAB report in its latest 8-K?

STANDARD BIOTOOLS INC. (LAB) filed an 8-K on November 19, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 7.01 (Regulation FD Disclosure) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved the Post-Closing Equity Incentive Plan and Post-Closing ESPP.

What are the latest LAB SEC filings?

STANDARD BIOTOOLS INC. (LAB) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 5, 2026.

What is LAB's SEC CIK number?

STANDARD BIOTOOLS INC. (LAB)'s SEC Central Index Key (CIK) is 1162194. EDGAR lists every LAB filing under that number.

Ask anything about LAB

The research agent reads LAB's filings, financials, insider trades and 13F holders, then answers with sources.